Literature DB >> 32816990

Gilead Buys into Tizona's Anti-HLA-G Strategy.

.   

Abstract

Gilead announced plans in July to pay $300 million for a 49.9% stake in Tizona Therapeutics, with the option to buy the rest of the company for $1.25 billion. Whether Gilead follows through with the acquisition will hinge on how well Tizona's investigational HLA-G inhibitor, TTX-080, fares in early-stage clinical trials. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID： 32816990     DOI： 10.1158/2159-8290.CD-NB2020-077

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  6 in total

1.  Effect of HLA-G5 Immune Checkpoint Molecule on the Expression of ILT-2, CD27, and CD38 in Splenic B cells.

Authors:  Hana Rohn; Cordula Lang; Sabine Schramm; Falko M Heinemann; Mirko Trilling; Anja Gäckler; Oliver Witzke; Peter A Horn; Vera Rebmann
Journal:  J Immunol Res       Date:  2022-05-12       Impact factor: 4.493

2.  Prognostic Significance of Immune Checkpoints HLA-G/ILT-2/4 and PD-L1 in Colorectal Cancer.

Authors:  Qiong-Yuan Chen; Yu-Xin Chen; Qiu-Yue Han; Jiang-Gang Zhang; Wen-Jun Zhou; Xia Zhang; Yao-Han Ye; Wei-Hua Yan; Aifen Lin
Journal:  Front Immunol       Date:  2021-05-13       Impact factor: 7.561

3.  An exploration of immunohistochemistry-based prognostic markers in patients undergoing curative resections for colon cancer.

Authors:  Astrid Louise Bjørn Bennedsen; Luyi Cai; Rune Petring Hasselager; Aysun Avci Özcan; Khadra Bashir Mohamed; Jens Ole Eriksen; Susanne Eiholm; Michael Bzorek; Anne-Marie Kanstrup Fiehn; Thomas Vauvert F Hviid; Ismail Gögenur
Journal:  BMC Cancer       Date:  2022-01-14       Impact factor: 4.430

Review 4.  Perspective of HLA-G Induced Immunosuppression in SARS-CoV-2 Infection.

Authors:  Aifen Lin; Wei-Hua Yan
Journal:  Front Immunol       Date:  2021-12-06       Impact factor: 7.561

5.  Comprehensive Transcriptomic Analysis Reveals the Role of the Immune Checkpoint HLA-G Molecule in Cancers.

Authors:  Hui-Hui Xu; Jun Gan; Dan-Ping Xu; Lu Li; Wei-Hua Yan
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

Review 6.  HLA-G/ILTs Targeted Solid Cancer Immunotherapy: Opportunities and Challenges.

Authors:  Aifen Lin; Wei-Hua Yan
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.